Primary Job Title Board of Directors Primary Organization 
Clementia Pharmaceuticals
From 2005-2012 Robert Heft served as President and Chief Executive Officer and member of the Board of Directors of Enobia Pharma Inc. (Montreal, Quebec). In February 2012 he sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 Billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Prior to Enobia he held several
senior positions with BioMarin Pharmaceutical Inc. (Novato, California) after selling the pharmaceutical assets of IBEX Pharmaceuticals Inc. (IBT:TSX, Montreal, Quebec) to BioMarin in 2001. Dr. Heft founded IBEX in 1986, and served as its President, Chief Scientist and member of its Board of Directors until 2001.
Dr. Heft served as Executive in Residence at Sectoral Asset Management, on the Board of Directors of; Clementia Pharmaceuticals, BioCapital (Private Equity/Venture Capital), the Canadian Genetic Diseases Network and the Industrial Biotechnology Association of Canada. Dr. Heft obtained his PhD from the Massachusetts Institute of Technology in Genetic Engineering/Radiological Sciences in 1986 and was a Neurology Fellow at the Massachusetts General Hospital.
Prior to that he received a Masters degree in Nuclear Engineering from Cornell University and a Bachelor of Mechanical Engineering from McGill University. Dr. Heft has been awarded several patents in the field of: coagulation, phenylketonuria and hypophosphatasia and has published in these fields. He has also received several awards for his work including: Company of the Year (Gold Leaf Award for Enobia Pharma) – 2012 BIOTECanada, Entrepreneur of the Year – Canada, 2012, Canadian Venture Capital Association, Genesis Award – 2012, from BioQuebec.
